CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up

Scott R. Gilles, Sophia L. Yohe, Michael A. Linden, Michelle Dolan, Betsy Hirsch, Bartosz Grzywacz

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Objectives: CD161 (NKRP1) is a lectin-like receptor present on NK cells and rare T-cell subsets. We have observed CD161 expression in some cases of T-cell prolymphocytic leukemia (T-PLL) and found it to be useful in follow-up and detection of disease after treatment. Methods: Retrospective review of T-PLL cases with complete flow cytometry data including CD161. Results: We identified 10 cases of T-PLL with flow cytometric evaluation of CD161 available. Six of these cases were positive for CD161 expression. All CD161-positive cases were positive for CD8 with variable CD4 expression, whereas all CD161-negative cases were negative for CD8. In a case with two neoplastic subsets positive and negative for CD8, only the former expressed CD161. Conclusions: These novel results suggest that CD161 is often aberrantly expressed in a defined subset of T-PLL positive for CD8. We are showing the utility of this immunophenotype in diagnosis and follow-up.

Original languageEnglish (US)
Pages (from-to)471-478
Number of pages8
JournalAmerican journal of clinical pathology
Volume152
Issue number4
DOIs
StatePublished - Sep 9 2019

Bibliographical note

Publisher Copyright:
© 2019 American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Keywords

  • CD161
  • Flow cytometry
  • Immunophenotype
  • NKR-P1A
  • T-cell lymphoma
  • T-cell prolymphocytic leukemia

Fingerprint

Dive into the research topics of 'CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up'. Together they form a unique fingerprint.

Cite this